A prospective case-control validation of procalcitonin as a biomarker diagnosing pacemaker and implantable cardioverter-defibrillator pocket infection

Knoll, Katharina; O’Connor, Matthew; Chouchane, Amir; Haller, Bernhard; Schaarschmidt, Claudia; Böck, Matthias; Förschner, Leonie; Fröhlich, Rebecca; Kottmaier, Marc; Bourier, Félix; Reents, T; Hessling, Gabriele; Deisenhofer, Isabel; Kolb, Christof; Lennerz, Carsten

doi:10.33963/kp.a2022.0124

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study included a total of 73 as case-control subjects that were from different phases of chronic myeloid leukemia (CML). The case-control based clinical validation of potential disease biomarker is a gold standard in discovery and clinical validation of novel biomarkers [36, 37]. We used NGS-based targeted resequencing and Sanger sequencing for clinical validation of ZNF G64A mutation as AP-/BC-CML.…”

Section: Discussionmentioning

confidence: 99%

A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia

Alanazi,

Siyal,

Basit

et al. 2024

Preprint

View full text Add to dashboard Cite

The hallmark of Chronic Myeloid Leukemia (CML) is Philadelphia chromosome t(9:22), which leads to formation of BCR-ABL1 fusion oncogene. BCR-ABL1 induces genetic instability, causing the progression of chronic myeloid leukemia (CML) from the manageable Chronic Phase (CP-CML) to the accelerated phase (AP-CML) and ultimately to the lethal blast crisis (BC-CML). The precise mechanism responsible for CML progression are not well comprehended, and there is a lack of specific molecular biomarkers for advanced phase CML. Mutations in transcription factors (TFs) have a significant role in cancer initiation, relapses, invasion, metastasis, and resistance to anti-cancer drugs. Recently, our group reported association of a novel transcription factor, ZNF208, with CML progression and there was a dire need for clinical validation of this novel biomarker. Therefore, the aim of this study was to clinically validate mutated ZNF208 as a novel biomarker for CML progression in a larger cohort of AP- and BC-CML patients using control-case studies. A total of 73 CML patients (N=73) from King Saud University Medical City Riyadh and King Abdulaziz National Guard Hospital, Al-Ahsa, Saudi Arabia were enrolled in the study (2020-2023) , with the experimental group (cases) consisting of patients AP-CML (n=20) and BC-CML (n=12). The controls consisted of age/sex matched CP-CML (n=41). The study was approved by Research Ethics Committees of participating institutes and all patients provided informed consent for the study. Clinical evaluations for patients were conducted according to the guidelines established by the European LeukemiaNet in 2020. Targeted resequencing of ZNF 208 was employed using Illumina NextSeq500 instrument (Illumina, San Diego, CA, USA) and mutations confirmed using Sanger sequencing. Both next generation sequencing as well as Sanger sequencing identified a novel missense mutation (c.64G>A) in novel ZNF208 . in 56 (93.3) and12 (100) CP-, AP- and BC-CML patients respectively, while in none (0%) of CP-CML patients or healthy controls from genomic databases (p=0.0001). Therefore, our studies show that ZNF208 mutation (c.64G>A) is novel and very specific biomarker for AP-and BC-CML patients. ZNF208 and other such proteins may cause carcinogenesis by interacting with KAP-1 repressor to silence many target genes and thus may prove to be novel drug targets as well. Therefore, we recommend carrying out prospective clinical trials for further clinical validation of this biomarker for its utilization in clinical decision, investigating its precise role in cancer pathogenesis and investigate its potential for novel drug target in advanced phase CML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia

Alanazi,

Siyal,

Basit

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Section: Diagnosismentioning

confidence: 99%

“…There are data regarding use of procalcitonin levels in the diagnosis of CIEDI that are preliminary but suggest that this biomarker may be useful in diagnosis and could be used to differentiate local (pocket site) versus systemic infection. 42,43 Clinical Perspective • The diagnostic accuracy of procalcitonin in CIEDI deserves further investigation. Use of procalcitonin may be considered in conjunction with other clinical, laboratory, and imaging data.…”

Section: Role Of Inflammatory Markers In the Diagnosis Of Ciedimentioning

confidence: 99%

Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association

Baddour,

Esquer Garrigos,

Rizwan Sohail

et al. 2024

Circulation

View full text Add to dashboard Cite

The American Heart Association sponsored the first iteration of a scientific statement that addressed all aspects of cardiovascular implantable electronic device infection in 2010. Major advances in the prevention, diagnosis, and management of these infections have occurred since then, necessitating a scientific statement update. An 11-member writing group was identified and included recognized experts in cardiology and infectious diseases, with a career focus on cardiovascular infections. The group initially met in October 2022 to develop a scientific statement that was drafted with front-line clinicians in mind and focused on providing updated clinical information to enhance outcomes of patients with cardiovascular implantable electronic device infection. The current scientific statement highlights recent advances in prevention, diagnosis, and management, and how they may be incorporated in the complex care of patients with cardiovascular implantable electronic device infection.

show abstract

“…Moreover, advances in diagnostics, including use of procalcitonin in the recognition of device pocket infection, have been done recently [12].…”

Section: Introductionmentioning

confidence: 99%

Infections of cardiac implantable electronic devices: Epidemiology, mechanisms, and preventive measures

Traykov,

Dzhinsov,

Matusik

2023

Kardiol Pol

View full text Add to dashboard Cite

Cardiac implantable electronic device (CIED) infections represent a complication associated with high morbidity and mortality. Despite enormous efforts to prevent them, the rates of infections continue to rise out of proportion to the reported increase in CIED implantation rates. Following extensive research of various prevention strategies and new technologies, several organizations have issued recommendations and consensus papers covering this topic. Our narrative review aims to provide a summary of the existing preventive strategies put forward by the European Heart Rhythm Association consensus and European Society of Cardiology guidelines and introduce the most recent developments in the field, including optimized surgical site management and appropriate periprocedural antithrombotic drug use. It also provides an overview of epidemiology, mechanisms, risk factors, and risk stratification approaches. It focuses on the pre-, intra-, and postprocedural actions that should be taken to mitigate CIED infection risks. Future directions in the prevention of CIED infections have also been addressed.

show abstract

A prospective case-control validation of procalcitonin as a biomarker diagnosing pacemaker and implantable cardioverter-defibrillator pocket infection

Cited by 3 publications

References 21 publications

A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia

A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia

Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association

Infections of cardiac implantable electronic devices: Epidemiology, mechanisms, and preventive measures

Contact Info

Product

Resources

About